drugset / Trial / NCT02988986
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Phase 2
Completed
28 enrolled
The Methodist Hospital Research Institute
Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.
Timeline
- Start
- 2017-04-24
- Primary completion
- 2019-02-01
- Completion
- 2019-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sapanisertib | Small molecule | 30 mg | Oral |
| Subject | Tamoxifen | Small molecule | 20 mg | Oral |